NL-OMON23213招募中不适用
A phase I trial evaluating the safety, tolerability and pharmacokinetics of intravenously administered M6229 in critically ill sepsis patients – HistoSeps”
Amsterdam UMC, location AMC0 个研究点目标入组 16 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients aged = 18 years old.
- •2. Signed informed consent by patient or legal representative.
- •3. ICU admittance for sepsis defined by the Sepsis-3 criteria as a life-threatening organ dysfunction caused by a dysregulated host response to an infection.
- •Organ dysfunction is defined by 1 of the following:
- •a. Increase in SOFA score of =2.
- •i. The baseline SOFA score can be assumed to be zero in patients not known to have pre-existing organ dysfunction.
- •b. Acute kidney injury
- •i. Defined as eGFR < 15 mL/min.
- •c. Acute respiratory distress syndrome
- •i. Defined by the Berlin criteria.
- •d. The need of mechanical ventilation.
- •e. Alteration in mental status.
- •4. The patients have to be included in the study within 72 hours of ICU admission due to sepsis. M6229 has to be administered within 84 hours after ICU admission due to sepsis.
排除标准
- •1. Subject has an advance directive to withhold life-sustaining treatments.
- •2. Subject is breastfeeding or intents to get pregnant within 30 days of enrolling into the study.
- •3. Subject is of childbearing potential and has a positive pregnancy test.
- •a. A woman is considered to be of childbearing potential under the age of 60 years, unless surgically sterile.
- •4. Clinical suspicion or confirmation of a viral hemorrhagic shock syndrome including, but not limited to, dengue fever.
- •5. Bleeding risk:
- •a. Clinical:
- •i. Active bleeding;
- •ii. Head trauma;
- •iii. Intracranial surgery or stroke in the past 3 months;
- •iv. History of intracerebral arteriovenous malformation, cerebral aneurysm or mass lesions of the central nervous system;
- •v. Cerebral haemorrhage;
- •vi. History of a bleeding diatheses;
- •vii. Gastrointestinal bleeding in the past 6 weeks;
- •viii. Presence of an epidural or spinal catheter;
- •ix. Contraindication for IV therapeutic UFH.
- •b. Laboratory:
- •i. Platelet count <50 x109/L;
- •ii. INR >2.0;
- •iii. Baseline aPTT =45 seconds prior to enrolment, 1.5x upper limit of normal (ULN).
- •6. Use of any of the following treatments:
- •a. UFH to treat a thrombotic event within 12 hours before enrolment;
- •b. LMWH at a higher dose than recommended for prophylactic use within 12 hours before the infusion;
- •c. Warfarin (if used within 7 days before study entry AND if the INR exceeds 2.0 at enrolment);
- •d. Direct oral anticoagulant (DOAC) use 3 days prior to enrollment.
- •e. Thrombolytic therapy within 3 previous days;
- •f. Use of IIb/IIIa inhibitors within the previous 7 days.
- •7. Confirmed antiphospholipid syndrome.
- •8. Known allergy to fish.
- •9. Cardiopulmonary resuscitation in the previous 7 days.
- •10. Liver failure defined as Child-Pugh Score Class C.
- •11. Abnormal liver function (ASAT and/or ALAT > 5 times upper limit of normal (ULN))..
- •12. Extracorporeal membrane oxygenation (ECMO) support dependent.
- •13. Pulmonary embolism or clinical suspicion of deep venous thrombosis (DVT).
- •14. Life expectancy of less than 24 hours.
- •15. Treating physician refusal.
- •16. Known adverse reaction to UFH, including heparin induced thrombocytopenia (HIT).
- •17. Participation in any other investigational drug study or other interventional study with interfering endpoints.
- •18. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol.
研究者
相似试验
已完成
不适用
A phase I trial evaluating the safety, tolerability and pharmacokinetics of intravenously administered M6229 in critically ill sepsis patients - *HistoSeps*SepsisNL-OMON51932Academisch Medisch Centrum26
已完成
1 期
A study of the safety of a novel treatment (PVX108) for peanut allergy, conducted in peanut-allergic adultsPeanut allergyInflammatory and Immune System - AllergiesACTRN12617000692336Aravax Pty Ltd66
已完成
1 期
Phase I trial of autologous cytomegalovirus (CMV)-specific T cells as adjuvant therapy for primary glioblastoma multiformeglioblastoma multiformaeCancer - BrainACTRN12615000656538QIMR Berghofer Medical Research Institute20
终止
1 期
A phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics and the Food Effect on the Safety and Pharmacokinetics of OPC-131066healthy adultJPRN-jRCT2080224712Otsuka Pharmaceutical Co., LTD.122
已完成
不适用
A Phase 1 trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of AS-0871 and to evaluate the relative bioavailability and the food effect of new oral formulations of AS-0871 in healthy subjects.NL-OMON53402Carna Biosciences, Inc.40